PMID,Title,Authors,Journal,Year,Abstract
36335326,"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease",Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J,Cardiovasc Diabetol,2022,"OBJECTIVE: To evaluate the cardiovascular and renal benefits of finerenone, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with Type 2 Diabetes Mellitus (T2 ..."
32819262,"Efficacy and Cardiovascular Safety of DPP-4 Inhibitors",Subrahmanyan NA, Koshy RM, Jacob K, Pappachan JM,Curr Drug Saf,2021,"Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins belong to the class of incretin mimetics. These drugs have been available on the market for the management of type 2 diabetes mellitus (T2DM) for over a decade. ...Small clin ..."
34248838,"Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation",Meier JJ,Front Endocrinol (Lausanne),2021,"Across the SUSTAIN program, once-weekly subcutaneous semaglutide 1.0 mg reduced HbA(1c) by 1.5-1.8% after 30-56 weeks, which was significantly more than sitagliptin, liraglutide, exenatide extended release, dulaglutide, canagliflozin, or insulin ..."
37828829,"Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus",Tsukamoto S, Tanaka S, Yamada T, Uneda K, Azushima K, Kinguchi S, Wakui H, Tamura K,Diabetes Obes Metab,2024,"Randomized controlled trials (RCTs) that compared GLP-1RAs or GIP/GLP-1RAs in Japanese patients with T2D were selected. ...Subcutaneous semaglutide showed a superior reduction in HbA1c compared with oral semaglutide. Both subcutaneous and oral ..."
29756388,"Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis",Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A, Bekiari E, Matthews DR, Tsapas A,Diabetes Obes Metab,2018,"AIMS: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. ...Both doses demonstrated superior glycaemic efficacy compared to other antidiabetic agents, including sit ..."
38635113,"Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review",Lava SAG, Laurence C, Di Deo A, Sekarski N, Burch M, Della Pasqua O,Paediatr Drugs,2024,"INTRODUCTION: In adults, sodium-glucose cotransporter type 2 inhibitors have revolutionised the treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. OBJECTIVE: We aimed to review information on compassionate use, clinical p ..."
30954510,"Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study",Ku EJ, Lee DH, Jeon HJ, Oh TK,Diabetes Res Clin Pract,2019,"AIMS: To directly compare the effectiveness and safety between two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, as part of a quadruple oral antidiabetic agents (OADs) in patients with inadequately controlled type 2 di ..."
39068060,"Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study",Cho YK, Kim KS, Lee BW, Hong JH, Yu JM, Lim S, Kim YA, Lee CB, Kim SS, Kwak SH, Lee WJ,Clin Ther,2024,"PURPOSE: The purpose of this study was to determine the efficacy and safety profile of pioglitazone compared with placebo (PBO) in patients with type 2 diabetes (T2D) inadequately controlled with metformin and dapagliflozin. METHODS: In this prospective, mult ..."
33074557,"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial",Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, Ning Z, Rasmussen S, Skj√∏th TV, Yuan G, Eliaschewitz FG,Diabetes Obes Metab,2021,"AIM: To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes (T2D) in a multiregional clini ..."
29573110,"SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis",Li D, Shi W, Wang T, Tang H,Diabetes Obes Metab,2018,"To assess the efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase-4 (DPP-4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta-ana ..."
